{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-070287","form_type":"8-K","ticker":"LRMR","cik":"0001374690","company_name":"Larimar Therapeutics, Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.096768+00:00","generated_at":"2026-05-21T14:02:46.948769+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Larimar Therapeutics holds 2025 Annual Meeting; all proposals pass","bullets":["Thomas E. Hamilton elected Class II director with 46.5M votes for, 4.3M withheld.","Advisory say-on-pay approved: 49.2M for, 1.4M against, 0.2M abstain.","Ratification of PricewaterhouseCoopers as auditor for 2025: 57.7M for, 10.9K against.","No other material proposals; all votes passed."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-070287","json":"https://secwatch.observer/filing/0000950170-25-070287.json","markdown":"https://secwatch.observer/filing/0000950170-25-070287.md","text":"https://secwatch.observer/filing/0000950170-25-070287.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374690/000095017025070287/0000950170-25-070287-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374690/000095017025070287/lrmr-20250513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T14:02:46.948769+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}